Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer | Robert Dreicer

Описание к видео Expert comment: Phase II trial of enfortumab vedotin in urothelial cancer | Robert Dreicer

ASCO expert Robert Dreicer comments on the enfortumab vedotin data reported at the meeting, and explains why the findings hold so much promise for advanced urothelial carcinoma patients who have progressed on prior therapy.

View more on Medicine Matters oncology: http://bit.ly/2XILQpM

More on ASCO 2019: http://bit.ly/2X1zOYa

Комментарии

Информация по комментариям в разработке

Похожие видео